Rilvegostomig Alternatives: How It Compares to Other PD-1 & TIGIT Inhibitors

Rilvegostomig vs Pembrolizumab (Keytruda)

The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT06692738) enrolling 880 participants, primary completion 2029-02.

Primary-endpoint values for NCT06692738 are not yet posted in the AACT results database.

Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.

Rilvegostomig vs Nivolumab (Opdivo)

The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT07431281) enrolling 2,130 participants, primary completion 2029-08.

Primary-endpoint values for NCT07431281 are not yet posted in the AACT results database.

Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.

Rilvegostomig vs Atezolizumab (Tecentriq)

The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT06921785) enrolling 1,220 participants, primary completion 2029-03.

Primary-endpoint values for NCT06921785 are not yet posted in the AACT results database.

Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.

Rilvegostomig vs Durvalumab (Imfinzi)

The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT07221253) enrolling 1,100 participants, primary completion 2029-07.

Primary-endpoint values for NCT07221253 are not yet posted in the AACT results database.

Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.

Beyond currently available options, several investigational drugs are advancing through Phase 3 development. Among these is Tiragolumab from Hoffmann-La Roche, an investigational agent with its lead Phase 3 trial identified as NCT04619797. This compound is approximately 1-2 years behind other advanced investigational alternatives. Also in Phase 3 is Pumitamig, developed by BioNTech SE, with its lead study listed under NCT06712316. Pumitamig represents a different mechanism of action, functioning as an IL-17A nanobody.

Choosing between Rilvegostomig and established PD-1 or PD-L1 inhibitors involves considering their distinct mechanisms of action. Rilvegostomig, as a PD-1/TIGIT bispecific antibody, targets two immune checkpoints simultaneously, which may offer a broader or enhanced immunomodulatory effect compared to agents that target only PD-1 or PD-L1. This dual mechanism could be a differentiating factor for clinicians seeking to engage multiple pathways in the tumor microenvironment. While specific efficacy data for Rilvegostomig is still emerging, its bispecific nature represents a novel approach in checkpoint inhibition.

Conversely, clinicians may opt for established PD-1 or PD-L1 inhibitors due to their extensive clinical experience and well-characterized efficacy and safety profiles across various indications. For instance, Pembrolizumab (Keytruda), a PD-1 inhibitor, has demonstrated an Overall Survival Hazard Ratio of 0.6 at 5 years, with dosing options of 200 mg every 3 weeks or 400 mg every 6 weeks intravenously. Nivolumab (Opdivo), another PD-1 inhibitor, has shown a median Overall Survival of 9.2 months, administered as 240 mg every 2 weeks or 480 mg every 4 weeks intravenously. Atezolizumab (Tecentriq), a PD-L1 inhibitor, has a median Overall Survival of 13.8 months with a 1200 mg intravenous dose every 3 weeks. Durvalumab (Imfinzi), also a PD-L1 inhibitor, has demonstrated a median Progression-Free Survival of 16.8 months, typically dosed at 1500 mg intravenously every 3 to 4 weeks. The choice among these agents often depends on specific patient characteristics, disease stage, prior treatments, and individual treatment goals, including considerations for dosing frequency.

This information is for comparative purposes only and is not intended as medical advice; clinical decisions should always be made by a qualified prescriber in consultation with the patient.